What Drives Institutional Interest in AbbVie Inc. (NYSE:ABBV)?

3 min read | February 11, 2025 04:21 AM PST | By Team Kalkine Media

What Drives Institutional Interest in AbbVie Inc. (NYSE:ABBV)? — Image source: Shutterstock

Institutional Holdings in AbbVie

Institutional investors have been increasing their stakes in AbbVie Inc. (NYSE:ABBV), a leading pharmaceutical company. Apollon Wealth Management LLC recently expanded its position in the company, acquiring additional shares in the fourth quarter. The firm’s total holdings reached 79,230 shares, valued at approximately $14.08 million, based on its latest filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also adjusted their holdings. Groupama Asset Management increased its stake by over 40% in the third quarter, while RPg Family Wealth Advisory LLC, Fiduciary Advisors Inc., and Retirement Wealth Solutions LLC acquired new stakes in the company. These adjustments indicate continued engagement from financial entities, reinforcing AbbVie’s standing among institutional investors.

Stock Performance and Trading Activity

AbbVie shares were actively traded in recent sessions. During Monday’s midday trading, the stock saw a slight decline of $0.29, settling at $190.31. Trading volume reached over 3.6 million shares, compared to an average daily volume exceeding 6.1 million shares. Over the past year, the stock has fluctuated between a low of $153.58 and a high of $207.32, reflecting price movements influenced by various market factors.

The company’s financial profile includes a market capitalization of approximately $336.30 billion. Liquidity ratios, such as a quick ratio of 0.54 and a current ratio of 0.65, provide insight into AbbVie’s short-term financial standing. Additionally, its debt-to-equity ratio of 9.64 highlights its capital structure and financial management approach.

Financial Metrics and Market Trends

AbbVie’s stock performance is often analyzed based on key financial indicators. The company's price-to-earnings (P/E) ratio stands at 79.29, and it holds a P/E/G ratio of 1.53. With a beta of 0.58, the stock exhibits lower volatility compared to broader market trends.

Technical indicators also play a role in market observations. AbbVie’s 50-day simple moving average is recorded at $177.54, while its 200-day simple moving average stands at $185.75. These figures provide a broader view of the stock’s movement over time.

Institutional Participation and Market Influence

Institutional investors and hedge funds collectively own over 70% of AbbVie’s shares, demonstrating their strong influence over the stock’s movement. This level of ownership indicates confidence in the company's performance and long-term outlook within the pharmaceutical sector.

AbbVie’s continued engagement with institutional investors highlights its established position within the industry. With consistent trading activity and financial performance metrics, the company remains a focal point among financial entities monitoring developments in the pharmaceutical sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.